2016 DEA Safety 
NORML
AUGUST 2, 2019
A federal court has ordered the Drug Enforcement Administration to respond to a lawsuit charging the agency with failing to move forward with a 2016 policy to expand the total number of federally licensed marijuana cultivators. “[This filing is] asking the court for an order compelling the DEA to process our application.
Project CBD
MARCH 7, 2025
Devitt expresses serious safety concerns. In response to its growing popularity, the DEA announced in 2016 that kratom would be placed in the restrictive Schedule I along with cannabis. However, the following year the DEA put off its decision pending further public commentary.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Canna Law Blog
JUNE 1, 2019
Drug Enforcement Administration (DEA) when it comes to DEA’s handling of petitions to remove marijuana from the list of most dangerous drugs. Schedule I is reserved for drugs with a high potential for abuse, no currently accepted medical uses, and a lack of accepted safety for medical use. You understand what I’m saying?
Cannabis Law Report
SEPTEMBER 9, 2019
The DEA’s announcement signals the “beginning of the end” of federal marijuana prohibition, as the policy change allows federal agencies to evaluate and assess the medical use and abuse potential of marijuana with (limited) political interference. BY EMILY BURNS, GREEN LIGHT LAW GROUP —.
Freedom Leaf
OCTOBER 15, 2018
On September 28, the DEA designated Epidiolex —a plant-based CBD pharmaceutical manufactured by the UK-based GW Pharmaceuticals—a Schedule V drug in the government’s list of controlled substances. schedules were created by the Controlled Substances Act (CSA) in 1970 and are interpreted and enforced by the DEA.
Cannabis Law Report
APRIL 8, 2022
Later that year, Doblin sued the DEA for the first time. The FDA formally decided to open the door to psychedelic research in human participants, and later accepted MAPS’ Phase 1 MDMA safety and tolerance study protocol. submitted his first DEA application to manufacture marijuana for use in medical research.
Cannabis Law Report
JULY 9, 2021
Drug Enforcement Agency (“DEA”). Some physicians and therapists have argued that the Right to Try Act permits them to administer psilocybin to terminally ill patients (since studies are well past the Phase 1 stage), but the DEA has met this with resistance given psilocybin’s status as a Schedule I drug. AIMS Institute, PLLC.
Expert insights. Personalized for you.
227 
Let's personalize your content